175 related articles for article (PubMed ID: 33402480)
1. MicroRNA Deregulation in Papillary Thyroid Cancer and its Relationship With BRAF V600E Mutation.
Celakovsky P; Kovarikova H; Chrobok V; Mejzlik J; Laco J; Vosmikova H; Chmelarova M; Ryska A
In Vivo; 2021; 35(1):319-323. PubMed ID: 33402480
[TBL] [Abstract][Full Text] [Related]
2. Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
Han PA; Kim HS; Cho S; Fazeli R; Najafian A; Khawaja H; McAlexander M; Dy B; Sorensen M; Aronova A; Sebo TJ; Giordano TJ; Fahey TJ; Thompson GB; Gauger PG; Somervell H; Bishop JA; Eshleman JR; Schneider EB; Witwer KW; Umbricht CB; Zeiger MA
Thyroid; 2016 Apr; 26(4):532-42. PubMed ID: 26950846
[TBL] [Abstract][Full Text] [Related]
3. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma.
Yip L; Kelly L; Shuai Y; Armstrong MJ; Nikiforov YE; Carty SE; Nikiforova MN
Ann Surg Oncol; 2011 Jul; 18(7):2035-41. PubMed ID: 21537871
[TBL] [Abstract][Full Text] [Related]
5. Association of MicroRNA Expression and BRAF
Pamedytyte D; Simanaviciene V; Dauksiene D; Leipute E; Zvirbliene A; Sarauskas V; Dauksa A; Verkauskiene R; Zilaitiene B
Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32316638
[TBL] [Abstract][Full Text] [Related]
6. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma.
Chou CK; Yang KD; Chou FF; Huang CC; Lan YW; Lee YF; Kang HY; Liu RT
J Clin Endocrinol Metab; 2013 Feb; 98(2):E196-205. PubMed ID: 23264400
[TBL] [Abstract][Full Text] [Related]
8. Cyto-Histological Profile of MicroRNAs as Diagnostic Biomarkers in Differentiated Thyroid Carcinomas.
Matos ML; Pinto M; Alves M; Canberk S; Gonçalves A; Bugalho MJ; Papoila AL; Soares P
Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540448
[TBL] [Abstract][Full Text] [Related]
9. BRAF mutation, selected miRNAs and genes expression in primary papillary thyroid carcinomas and local lymph node metastases.
Kalfert D; Ludvikova M; Pesta M; Hakala T; Dostalova L; Grundmannova H; Windrichova J; Houfkova K; Knizkova T; Ludvik J; Polivka J; Kholova I
Pathol Res Pract; 2024 Jun; 258():155319. PubMed ID: 38696857
[TBL] [Abstract][Full Text] [Related]
10. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation.
Chou CK; Chen RF; Chou FF; Chang HW; Chen YJ; Lee YF; Yang KD; Cheng JT; Huang CC; Liu RT
Thyroid; 2010 May; 20(5):489-94. PubMed ID: 20406109
[TBL] [Abstract][Full Text] [Related]
11. BRAF
Gao Y; Xiang D; Li W; Zheng X; Wang L; Li Z; Chen T
Front Endocrinol (Lausanne); 2022; 13():843334. PubMed ID: 35651980
[No Abstract] [Full Text] [Related]
12. MicroRNA-150-5p affects cell proliferation, apoptosis, and EMT by regulation of the BRAF
Yan R; Yang T; Zhai H; Zhou Z; Gao L; Li Y
J Cell Biochem; 2018 Nov; 119(11):8763-8772. PubMed ID: 30126001
[TBL] [Abstract][Full Text] [Related]
13. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
[TBL] [Abstract][Full Text] [Related]
14. Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma.
Sheu SY; Grabellus F; Schwertheim S; Handke S; Worm K; Schmid KW
Horm Metab Res; 2009 Jun; 41(6):482-7. PubMed ID: 19370505
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-146b: A Novel Biomarker and Therapeutic Target for Human Papillary Thyroid Cancer.
Chou CK; Liu RT; Kang HY
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28294980
[TBL] [Abstract][Full Text] [Related]
16. Papillary Thyroid Carcinoma: Molecular Distinction by MicroRNA Profiling.
Galuppini F; Censi S; Merante Boschin I; Fassan M; Sbaraglia M; Valeri N; Hahne JC; Bertazza L; Munari G; Galasso M; Cascione L; Barollo S; Rugge M; Vianello F; Dei Tos AP; Mian C; Pennelli G
Front Endocrinol (Lausanne); 2022; 13():834075. PubMed ID: 35282462
[TBL] [Abstract][Full Text] [Related]
17. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer.
Geraldo MV; Nakaya HI; Kimura ET
Oncotarget; 2017 Feb; 8(6):9597-9607. PubMed ID: 28030816
[TBL] [Abstract][Full Text] [Related]
19. In-depth characterization of the microRNA transcriptome in normal thyroid and papillary thyroid carcinoma.
Swierniak M; Wojcicka A; Czetwertynska M; Stachlewska E; Maciag M; Wiechno W; Gornicka B; Bogdanska M; Koperski L; de la Chapelle A; Jazdzewski K
J Clin Endocrinol Metab; 2013 Aug; 98(8):E1401-9. PubMed ID: 23783103
[TBL] [Abstract][Full Text] [Related]
20. BRAF V600E mutation and microRNAs are helpful in distinguishing papillary thyroid malignant lesions: Tissues and fine needle aspiration cytology cases.
Zarkesh M; Zadeh-Vakili A; Akbarzadeh M; Nozhat Z; Fanaei SA; Hedayati M; Azizi F
Life Sci; 2019 Apr; 223():166-173. PubMed ID: 30890403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]